Becker's Healthcare November 14, 2024
The FDA continues to face significant staffing shortages in its drug inspection workforce, according to a new report from the Government Accountability Office.
Despite some progress in resuming in-person inspections after COVID-19 disruptions, the report showed that the FDA is struggling to keep pace with the growing demand for oversight, particularly in foreign drug manufacturing.
The GAO’s findings highlight that while the FDA conducted 621 foreign and 444 domestic inspections in fiscal 2023, the total number of inspections was still 36% lower than pre-pandemic levels in 2019. The agency attributes the shortfall to reduced investigator capacity, exacerbated by...
Today's Sponsors
Today's Sponsor